{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:12:38Z","timestamp":1778584358790,"version":"3.51.4"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>With the rise in long-term medication use, assessing ocular adverse reactions (OARs) from systemic drugs has gained importance. Using large real-world databases like the FDA Adverse Event Reporting System (FAERS) offers valuable clinical and pharmacovigilance insights.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Disproportionality analysis, including the ratio of reported odds (ROR), was performed on all OAR reports related to systemic medications in the FAERS database from 2004 Q1 to 2024 Q3. The OARs were categorized into disease-based and symptom-based classifications to identify systemic medications with positive signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In the FAERS database, the most common OARs were cataract, dry eye, and glaucoma, with blurred vision, visual impairment, and eye pain as the leading symptoms. Through disproportionality analysis, 141 systemic medications with positive signal drugs for OAR risks were identified, which were concentrated in the following categories: antineoplastic medication [30 drugs, belantamab mafodotin ROR (95% confidence interval): 59.59 (56.25\u201363.13)], central nervous system medication [21 drugs, fingolimod, 2.69 (2.63\u20132.75)], anti-infective medication [15 drugs, moxifloxacin, 6.52 (6.21\u20136.84)], immunological and inflammation-related medication [15 drugs, dupilumab, 4.74 (4.7\u20134.79)], cardiovascular system medication [10 drugs, ivabradine, 3.06 (2.61\u20133.58)], endocrine and metabolic disease medication [10 drugs, insulin lispro, 3.63 (3.4\u20133.89)], respiratory system medication [6 drugs, telithromycin, 3.51 (3.14\u20133.93)], and other medication [34 drugs, botulinum toxin type A, 4.24 (4.12\u20134.36)].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This pharmacovigilance study underscores the importance of identifying under-recognized OARs from systemic drugs to prevent secondary eye diseases and improve drug safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000003603","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:00:32Z","timestamp":1760605232000},"page":"2288-2300","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Retrospective cohort study of ocular adverse reactions to systemic drugs: insights from a multi-country spontaneous reporting database"],"prefix":"10.1097","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6992-9059","authenticated-orcid":false,"given":"Shi-Nan","family":"Wu","sequence":"first","affiliation":[{"name":"Xiamen University Affiliated Xiamen Eye Center; Fujian Provincial Key Laboratory of Ophthalmology and Visual Science; Fujian Engineering and Research Center of Eye Regenerative Medicine; Eye Institute of Xiamen University; School of Medicine, Xiamen University, Xiamen, Fujian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caihong","family":"Huang","sequence":"additional","affiliation":[{"name":"Xiamen University Affiliated Xiamen Eye Center; Fujian Provincial Key Laboratory of Ophthalmology and Visual Science; Fujian Engineering and Research Center of Eye Regenerative Medicine; Eye Institute of Xiamen University; School of Medicine, Xiamen University, Xiamen, Fujian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Dong","family":"Chen","sequence":"additional","affiliation":[{"name":"Xiamen University Affiliated Xiamen Eye Center; Fujian Provincial Key Laboratory of Ophthalmology and Visual Science; Fujian Engineering and Research Center of Eye Regenerative Medicine; Eye Institute of Xiamen University; School of Medicine, Xiamen University, Xiamen, Fujian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian-Ting","family":"Liu","sequence":"additional","affiliation":[{"name":"Xiamen University Affiliated Xiamen Eye Center; Fujian Provincial Key Laboratory of Ophthalmology and Visual Science; Fujian Engineering and Research Center of Eye Regenerative Medicine; Eye Institute of Xiamen University; School of Medicine, Xiamen University, Xiamen, Fujian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[{"name":"Xiamen University Affiliated Xiamen Eye Center; Fujian Provincial Key Laboratory of Ophthalmology and Visual Science; Fujian Engineering and Research Center of Eye Regenerative Medicine; Eye Institute of Xiamen University; School of Medicine, Xiamen University, Xiamen, Fujian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shao-Pan","family":"Wang","sequence":"additional","affiliation":[{"name":"Xiamen University Affiliated Xiamen Eye Center; Fujian Provincial Key Laboratory of Ophthalmology and Visual Science; Fujian Engineering and Research Center of Eye Regenerative Medicine; Eye Institute of Xiamen University; School of Medicine, Xiamen University, Xiamen, Fujian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaoyue","family":"Hu","sequence":"additional","affiliation":[{"name":"Xiamen University Affiliated Xiamen Eye Center; Fujian Provincial Key Laboratory of Ophthalmology and Visual Science; Fujian Engineering and Research Center of Eye Regenerative Medicine; Eye Institute of Xiamen University; School of Medicine, Xiamen University, Xiamen, Fujian, China"},{"name":"Department of Ophthalmology, Xiang\u2019an Hospital of Xiamen University, Xiamen, Fujian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuguo","family":"Liu","sequence":"additional","affiliation":[{"name":"Xiamen University Affiliated Xiamen Eye Center; Fujian Provincial Key Laboratory of Ophthalmology and Visual Science; Fujian Engineering and Research Center of Eye Regenerative Medicine; Eye Institute of Xiamen University; School of Medicine, Xiamen University, Xiamen, Fujian, China"},{"name":"Department of Ophthalmology, Xiang\u2019an Hospital of Xiamen University, Xiamen, Fujian, China"},{"name":"Department of Ophthalmology, The First Affiliated Hospital of University of South China, Hengyang, Hunan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"R1-20260512","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1186\/s12889-024-20607-5","article-title":"Trends in the prevalence and burden of blindness and vision loss among adolescents aged 10-24 years in the western pacific region over 30 years","volume":"24","author":"Luo","year":"2024","journal-title":"BMC Public Health"},{"key":"R2-20260512","doi-asserted-by":"crossref","first-page":"575\u201387","DOI":"10.1016\/j.ophtha.2023.02.002","article-title":"Global, regional, and national burdens of blindness and vision loss in children and adolescents from 1990 to 2019: a trend analysis","volume":"130","author":"Liu","year":"2023","journal-title":"Ophthalmology"},{"key":"R3-20260512","doi-asserted-by":"crossref","first-page":"534\u201344","DOI":"10.1016\/j.ophtha.2023.11.023","article-title":"Disability-adjusted life years resulting from ocular injury among deployed service members, 2001-2020","volume":"131","author":"Travor","year":"2024","journal-title":"Ophthalmology"},{"key":"R4-20260512","doi-asserted-by":"crossref","first-page":"112\u201319","DOI":"10.1016\/j.jtos.2024.01.009","article-title":"Association between systemic medication use and severity of dry eye signs and symptoms in the DRy eye assessment and management (DREAM) study","volume":"32","author":"Guo","year":"2024","journal-title":"Ocul Surf"},{"key":"R5-20260512","doi-asserted-by":"crossref","first-page":"100104","DOI":"10.1016\/j.apjo.2024.100104","article-title":"Real-world large sample assessment of drug-related dry eye risk: based on the FDA adverse event reporting system database","volume":"13","author":"Wu","year":"2024","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"R6-20260512","doi-asserted-by":"crossref","first-page":"203\u201304","DOI":"10.1001\/jamaophthalmol.2016.5335","article-title":"The association of systemic medication and disease with intraocular pressure","volume":"135","author":"Foster","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"R7-20260512","first-page":"140","article-title":"Drug-associated glaucoma: a real-world study based on the food and drug administration adverse event reporting system database","author":"Wu","journal-title":"Clin Exp Ophthalmol"},{"key":"R8-20260512","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1167\/tvst.13.9.17","article-title":"Drug-related keratitis: a real-world FDA adverse event reporting system database study","volume":"13","author":"Wu","year":"2024","journal-title":"Transl Vis Sci Technol"},{"key":"R9-20260512","doi-asserted-by":"crossref","first-page":"1\u201313","DOI":"10.1016\/j.ajo.2023.09.027","article-title":"NSAIDs and corticosteroids for the postoperative management of age-related cataract surgery: a systematic review and meta-analysis","volume":"260","author":"Haddad","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"R10-20260512","doi-asserted-by":"crossref","first-page":"652\u201357","DOI":"10.1016\/j.ophtha.2008.12.001","article-title":"Use of inhaled and oral corticosteroids and the long-term risk of cataract","volume":"116","author":"Wang","year":"2009","journal-title":"Ophthalmology"},{"key":"R11-20260512","doi-asserted-by":"crossref","first-page":"352\u201360","DOI":"10.1016\/j.ophtha.2015.09.046","article-title":"Association between antiplatelet or anticoagulant drugs and retinal or subretinal hemorrhage in the comparison of age-related macular degeneration treatments trials","volume":"123","author":"Ying","year":"2016","journal-title":"Ophthalmology"},{"key":"R12-20260512","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA Adverse Event Reporting System (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R13-20260512","doi-asserted-by":"crossref","first-page":"101967","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"EClinicalMedicine"},{"key":"R14-20260512","first-page":"100081","article-title":"Revised strengthening the reporting of cohort, cross-sectional and case-control studies in surgery (STROCSS) guideline: an update for the age of Artificial Intelligence","volume":"10","author":"Agha","year":"2025","journal-title":"Premier J Sci"},{"key":"R15-20260512","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the drugbank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"R16-20260512","doi-asserted-by":"crossref","first-page":"109\u201317","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"R17-20260512","doi-asserted-by":"crossref","first-page":"65\u201371","DOI":"10.1111\/jcpt.13024","article-title":"Time-to-onset analysis of amiodarone-associated thyroid dysfunction","volume":"45","author":"Kinoshita","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"R18-20260512","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1038\/s41598-024-84679-4","article-title":"Real world pharmacovigilance assessment of drug related macular degeneration risks","volume":"15","author":"Chen","year":"2025","journal-title":"Sci Rep"},{"key":"R19-20260512","doi-asserted-by":"crossref","first-page":"191\u201398","DOI":"10.1016\/j.jclinepi.2021.07.014","article-title":"A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases","volume":"139","author":"Khouri","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"R20-20260512","doi-asserted-by":"crossref","first-page":"623\u201325","DOI":"10.2165\/00002018-200730070-00011","article-title":"Bayesian confidence propagation neural network","volume":"30","author":"Bate","year":"2007","journal-title":"Drug Saf"},{"key":"R21-20260512","doi-asserted-by":"crossref","first-page":"622\u201330","DOI":"10.1002\/pds.2247","article-title":"Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and multi-item gamma poisson shrinker","volume":"21","author":"Berlin","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R22-20260512","doi-asserted-by":"crossref","first-page":"e021122","DOI":"10.1136\/bmjopen-2017-021122","article-title":"The validity of the Rx-Risk comorbidity index using medicines mapped to the anatomical therapeutic chemical (ATC) classification system","volume":"8","author":"Pratt","year":"2018","journal-title":"BMJ Open"},{"key":"R23-20260512","doi-asserted-by":"crossref","first-page":"62\u201378","DOI":"10.1016\/j.ophtha.2024.07.008","article-title":"Cardiovascular and cerebrovascular adverse events associated with intravitreal anti-VEGF monoclonal antibodies: a world health organization pharmacovigilance study","volume":"132","author":"Yang","year":"2025","journal-title":"Ophthalmology"},{"key":"R24-20260512","doi-asserted-by":"crossref","first-page":"741\u201343","DOI":"10.1016\/j.ophtha.2024.01.020","article-title":"Ophthalmologic complications in coronavirus disease 2019 immunization: a national vaccine adverse event reporting system analysis","volume":"131","author":"Aftab","year":"2024","journal-title":"Ophthalmology"},{"key":"R25-20260512","doi-asserted-by":"crossref","first-page":"37\u201342","DOI":"10.1001\/jamaophthalmol.2021.4778","article-title":"Association between pentosan polysulfate sodium and retinal disorders","volume":"140","author":"McGwin","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"R26-20260512","first-page":"1\u20139","article-title":"Real-world analysis of medications inducing meibomian gland dysfunction: based on the FDA adverse event reporting system database","author":"Li","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"R27-20260512","doi-asserted-by":"crossref","first-page":"349\u201351","DOI":"10.2165\/00128071-200102060-00001","article-title":"Do women have more adverse drug reactions?","volume":"2","author":"Rademaker","year":"2001","journal-title":"Am J Clin Dermatol"},{"key":"R28-20260512","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.2196\/publichealth.9282","article-title":"Why clinicians don\u2019t report adverse drug events: qualitative study","volume":"4","author":"Hohl","year":"2018","journal-title":"JMIR Public Health Surveill"},{"key":"R29-20260512","doi-asserted-by":"crossref","first-page":"114681","DOI":"10.1016\/j.biopha.2023.114681","article-title":"Reports analysis of psychotropic drugs related adverse reactions in Australia and Poland during the COVID 19 pandemic","volume":"162","author":"Schetz","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"R30-20260512","doi-asserted-by":"crossref","first-page":"408\u201321","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"key":"R31-20260512","doi-asserted-by":"crossref","first-page":"937\u201348","DOI":"10.1111\/all.16045","article-title":"Dupilumab-associated ocular surface disease is characterized by a shift from Th2\/Th17 toward Th1\/Th17 inflammation","volume":"79","author":"Thormann","year":"2024","journal-title":"Allergy"},{"key":"R32-20260512","doi-asserted-by":"crossref","first-page":"459\u201373","DOI":"10.1111\/bjd.18276","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"key":"R33-20260512","doi-asserted-by":"crossref","first-page":"438\u201344","DOI":"10.1016\/j.ophtha.2018.10.013","article-title":"Uveitis in patients with multiple sclerosis in clinical trials of fingolimod: incidence, prevalence, and impact on disease course","volume":"126","author":"Lim","year":"2019","journal-title":"Ophthalmology"},{"key":"R34-20260512","doi-asserted-by":"crossref","first-page":"789\u2013802","DOI":"10.1007\/s40265-013-0055-x","article-title":"Drug-induced macular edema","volume":"73","author":"Makri","year":"2013","journal-title":"Drugs"},{"key":"R35-20260512","doi-asserted-by":"crossref","first-page":"619\u201323","DOI":"10.1002\/onco.13756","article-title":"Overview of ocular side effects of selinexor","volume":"26","author":"Al-Zubidi","year":"2021","journal-title":"Oncologist"},{"key":"R36-20260512","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12913-019-4651-7","article-title":"Adverse drug reactions in primary care: a scoping review","volume":"20","author":"Khalil","year":"2020","journal-title":"BMC Health Serv Res"},{"key":"R37-20260512","doi-asserted-by":"crossref","first-page":"463\u201373","DOI":"10.1007\/s41999-021-00481-9","article-title":"Adverse drug reactions in older adults: a narrative review of the literature","volume":"12","author":"Zazzara","year":"2021","journal-title":"Eur Geriatr Med"},{"key":"R38-20260512","doi-asserted-by":"crossref","first-page":"886377","DOI":"10.3389\/fphar.2022.886377","article-title":"An updated review of genetic associations with severe adverse drug reactions: translation and implementation of pharmacogenomic testing in clinical practice","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"R39-20260512","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.ophtha.2009.05.014","article-title":"Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis","volume":"116","author":"McDonald","year":"2009","journal-title":"Ophthalmology"},{"key":"R40-20260512","doi-asserted-by":"crossref","first-page":"89\u201399","DOI":"10.2165\/11205840-000000000-00000","article-title":"Moxifloxacin 0.5% ophthalmic solution: in bacterial conjunctivitis","volume":"71","author":"Keating","year":"2011","journal-title":"Drugs"},{"key":"R41-20260512","doi-asserted-by":"crossref","first-page":"81\u201384","DOI":"10.1001\/jamaophthalmol.2014.3598","article-title":"Risk for uveitis with oral moxifloxacin: a comparative safety study","volume":"133","author":"Eadie","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R42-20260512","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/eye.2010.19","article-title":"Uveitis-like syndrome and iris transillumination after the use of oral moxifloxacin","volume":"24","author":"Willermain","year":"2010","journal-title":"Eye (Lond)"},{"key":"R43-20260512","doi-asserted-by":"crossref","first-page":"1112\u201314","DOI":"10.1016\/j.ophtha.2021.03.022","article-title":"Hydroxychloroquine prescription practices after 2016 american academy of ophthalmology recommendations","volume":"128","author":"Chen","year":"2021","journal-title":"Ophthalmology"},{"key":"R44-20260512","doi-asserted-by":"crossref","first-page":"874\u201376","DOI":"10.1016\/j.ophtha.2023.04.015","article-title":"Mitigating hydroxychloroquine toxicity with a clinical decision support tool","volume":"130","author":"Mehta","year":"2023","journal-title":"Ophthalmology"},{"key":"R45-20260512","doi-asserted-by":"crossref","first-page":"1004\u201313","DOI":"10.1016\/j.ophtha.2022.05.002","article-title":"Rapid macular thinning is an early indicator of hydroxychloroquine retinal toxicity","volume":"129","author":"Melles","year":"2022","journal-title":"Ophthalmology"},{"key":"R46-20260512","doi-asserted-by":"crossref","first-page":"72\u201378","DOI":"10.1016\/j.ophtha.2014.07.051","article-title":"Diabetes, fasting glucose, and the risk of glaucoma: a meta-analysis","volume":"122","author":"Zhao","year":"2015","journal-title":"Ophthalmology"},{"key":"R47-20260512","doi-asserted-by":"crossref","first-page":"893\u2013906","DOI":"10.1016\/j.ophtha.2023.05.001","article-title":"Association of systemic medication use with glaucoma and intraocular pressure: the european eye epidemiology consortium","volume":"130","author":"Vergroesen","year":"2023","journal-title":"Ophthalmology"},{"key":"R48-20260512","doi-asserted-by":"crossref","first-page":"490\u201396","DOI":"10.1016\/j.ophtha.2018.11.028","article-title":"Evolution in the risk of cataract surgical complications among patients exposed to tamsulosin: a population-based study","volume":"126","author":"Campbell","year":"2019","journal-title":"Ophthalmology"},{"key":"R49-20260512","doi-asserted-by":"crossref","first-page":"29\u201343","DOI":"10.1007\/s40264-015-0351-3","article-title":"An empirical approach to explore the relationship between measures of disproportionate reporting and relative risks from analytical studies","volume":"39","author":"Maci\u00e1-Mart\u00ednez","year":"2016","journal-title":"Drug Saf"},{"key":"R50-20260512","first-page":"1584","article-title":"Integrative epidemiology and immunotranscriptomics uncover a risk and potential mechanism for cutaneous lymphoma unmasking or progression with dupilumab therapy","author":"Cabrera-Perez","journal-title":"J Allergy Clin Immunol"},{"key":"R51-20260512","doi-asserted-by":"crossref","first-page":"891\u2013900","DOI":"10.1007\/s40257-021-00625-4","article-title":"DPP-4 inhibitors and increased reporting odds of bullous pemphigoid: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020","volume":"22","author":"Jedlowski","year":"2021","journal-title":"Am J Clin Dermatol"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000003603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:28:19Z","timestamp":1778581699000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000003603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000003603","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"2025-05-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}